Nuclear Medicine

Nuclear medicine (also called molecular imaging) includes positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. Nuclear imaging is achieved by injecting small amounts of radioactive material (radiopharmaceuticals) into patients before or during their scan. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

RSS icon

ASNC publishes new amyloidosis imaging guidelines

“We anticipate that these expert multisocietal consensus recommendations on multimodality imaging in cardiac amyloidosis will standardize the diagnosis and improve the management of this highly morbid and underdiagnosed disease," wrote authors of the new guidelines published in the Journal of Nuclear Cardiology.

September 9, 2019

Nuclear medicine, cardio groups reject proposed myocardial PET cuts

Multiple nuclear medicine and cardiology groups are working to oppose potential cuts to myocardial PET scans that were made possible by the CMS 2020 Medicare Physician Fee Schedule (MPFS) proposed rule, according to a joint statement.

September 6, 2019

Industry groups oppose proposed myocardial PET cuts

When CMS released the 2020 Medicare Physician Fee Schedule (MPFS) proposed rule, it included revisions that could lead to technical component payment reductions of up to 80% for certain services related to myocardial PET scans.

September 5, 2019

SNMMI introduces newest officers during annual conference

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) continued a busy four-day stretch by introducing several new officers during its 2019 Annual Meeting in Anaheim, California.

June 25, 2019

SNMMI presents 2 prestigious awards at annual conference

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) presented two prestigious awards during its 2019 Annual Meeting in Anaheim, California.

June 24, 2019

SHINE gains exclusive license for Lu-177 radioisotope production

Janesville, Wisconsin-based SHINE Medical Technologies has announced an agreement with the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), gaining exclusive rights over an innovation to produce lutetium-177 (Lu-177).

May 16, 2019
Medical societies are asking Congress to be involved in Medicare reform efforts.

SNMMI names recipient of annual government relations fellowship

The Society of Nuclear Medicine & Molecular Imaging (SNMMI) announced that Courtney Lawhn-Heath, MD, has been awarded the 2019 Robert E. Henkin Government Relations Fellowship.

April 24, 2019
charts reporting graph data

ACR, SNMMI collaborate on new clinical data registry

The American College of Radiology (ACR) and Society of Nuclear Medicine and Molecular Imaging (SNMMI) have joined forces to launch a new nuclear medicine clinical data registry.

April 10, 2019
Displaying 233 - 240 of 259
Design by Adaptive Theme